Full-Time
Project Management Assistant
Novonesis
5,001-10,000 employees
No salary listed
Walsrode, Germany
Hybrid
Hybrid role; low travel (max 10%).
 Business & Strategy (1) |
|---|
- Industrial Clerk, Administrative Assistant or equal education and have initial experience (2-3 years) in a project environment in the industry
- Must be proficient in using Microsoft Office software
- Must work well in a team environment and be a strong driver of change and process improvements
- Abilities to effectively facilitate corporation between departments and across sites to achieve desired results and have a strong focus on meeting deadlines
- Must be well organized and self-motivated, while demonstrating flexibility with regards to changes in priorities and business requirements
- Are systematic, detailed-oriented and have a strong analytical reasoning and problem-solving ability
- Effective written and oral communication skills
- Strong attention to detail and organizational skills
- Fluency in both written and oral German and English
- This position involves low travel activity, estimated max 10%
- Support risk identification, tracking, and maintenance of project risk registers, mitigation and control strategy
- Prepare purchase requisitions, coordinate with procurement, track deliveries, and ensure proper goods receipt documentation
- Monitor project costs, compare actuals vs. budgets, maintain SAP reports, and support financial forecasting
- Support and facilitate meetings and communication between departments and stakeholders connected to the projects, in cooperation with the project manager
- Support with assistance for driving the project documentation and collection of component data flow through all phases of a project, in close corporation with the project manager
- Provide general project management support such as preparing presentations, tracking action items, and assisting with planning tasks
Company Size
5,001-10,000
Company Stage
Debt Financing
Total Funding
$1.9B
Headquarters
Kongens Lyngby, Denmark
Founded
2024
Simplify's Take
What believers are saying
- Acquired Thailand facility from Meihua for $50M, operational by 2027.
- Secured dsm-firmenich Feed Enzyme Alliance control in June 2025.
- Posted 7% organic sales growth and €770M free cash flow in 2025.
What critics are saying
- Søren Linding deems Chr. Hansen merger value-destroying until 2030.
- €1.7B bonds at 3.25-4% expose to rising European rates by 2028.
- UCO surplus crashes biofuel margins, hitting Planetary Health sales in 2027.
What makes Novonesis unique
- Novonesis merges Novozymes and Chr. Hansen expertise in enzymes and biosolutions.
- GROW strategy targets 2030 growth via core acceleration and emerging markets.
- Launched Termamyl Prime enhances high-gravity brewing efficiency in 2026.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Novonesis who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Health Savings Account/Flexible Spending Account
Paid Vacation
Paid Holidays
Parental Leave
Tuition Reimbursement
Flexible Work Hours
Hybrid Work Options
Company News
Novonesis expands global footprint with acquisition of production facility in Southeast Asia. Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company's long-term growth ambitions. COPENHAGEN, Denmark - April 8, 2026. Novonesis has signed an agreement with Meihua to acquire a production facility in Rayong, Thailand for around USD 50 million, increasing the company's footprint in Southeast Asia and strengthening its ability to serve customers worldwide. Expanding in Asia is core to Novonesis' GROW strategy towards 2030. Emerging markets already account for one third of the company's sales and are expected to grow faster than developed markets. By investing in geographically well-positioned facilities, the company strengthens its capabilities to supply both local and global markets with its unique global multipurpose production setup. Novonesis is acquiring a facility with advanced fermentation capabilities that can be further expanded to support the company's growth journey, including the production of HMO (human milk oligosaccharides). Novonesis plans to invest further in the facility over the coming years to maximize its potential and establish a strong operational setup. The company expects the site to be commercially operational in 2027. Anders Lund, Chief Operating Officer: "Strengthening our production footprint in Southeast Asia is an important step for Novonesis. A key part of our GROW strategy is to continue to strengthen our resilient and responsive supply network to support our long-term growth ambitions. By expanding our world-class production capabilities, we can move closer to customers in a fast-growing region and deliver even greater value to them." Novonesis investing in capacity and resilience across markets The Rayong acquisition is one of several investments Novonesis has made in recent years to strengthen its resilience and global production setup - enabling the company to serve local customers more effectively and drive growth. Facilities in Franklinton, North Carolina, Taicang, China, Araucaria, Brazil, and West Allis, Wisconsin, have been expanded as part of this effort. Over the current strategy period towards 2030, Novonesis expects to increase its growth-focused capital expenditure and cater for the increasing demand for biosolutions among customers and consumers. Get in touch Line Emilie Fedders Senior Media Relations Manager [email protected]+45 30 77 13 99
Novonesis to host Sen. Pete Ricketts for manufacturing tour to highlight success of pro-growth tax policy. Washington, D.C. - Novonesis, in partnership with the National Association of Manufacturers, will host Sen. Pete Ricketts (R-NE) for a facility visit in Blair, Nebraska, on March 31 to highlight the impact of the pro-growth tax provisions of the Working Families Tax Cuts on America's manufacturing economy. The 2025 law made key tax policies permanent, including 100% bonus depreciation and full expensing for qualifying capital investment - policies that Novonesis can leverage as it continues to expand its plant in Blair. Novonesis has a significant footprint in Nebraska, having completed several large-scale expansions over the past 15 years, and the company continues to look to Blair for additional growth opportunities in the future. These investments underscore the site's evolution as a leading U.S. biomanufacturing hub. In addition, no tax on overtime directly benefits the facility's manufacturing workforce and supports recruitment and retention of skilled workers. Registered members of the press are invited to join the facility tour. Sen. Pete Ricketts Kyle Nixon, Novonesis Senior Director of Supply Chain for the Americas WHEN: March 31 at 9:45 a.m. CDT WHERE: 600 S. 1st St., Blair, NE 68008 WHY: The Working Families Tax Cuts' pro-growth tax provisions saved 37,000 jobs and $3.3 billion in wages in Nebraska alone. Novonesis' facility in Blair is a cornerstone of the company's U.S. manufacturing footprint, producing enzymes and advanced food ingredients for industries worldwide. The biosolutions firm is one of the many businesses in Nebraska that will benefit from continued pro-growth tax policy championed by Sen. Ricketts. The National Association of Manufacturers is the largest manufacturing association in the United States, representing small and large manufacturers in every industrial sector and in all 50 states. Manufacturing employs nearly 13 million men and women, contributes $2.95 trillion to the U.S. economy annually and accounts for 53% of private-sector research and development. The NAM is the powerful voice of the manufacturing community and the leading advocate for a policy agenda that helps manufacturers compete in the global economy and create jobs across the United States. For more information about the NAM or to follow us on Twitter and Facebook, please visit www.nam.org.
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility. COPENHAGEN, Denmark - March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis' purchase of the dsm firmenich's part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance's sales and distribution, strengthening the company's position across the animal biosolutions value chain. Rainer Lehmann, CFO: "The significant interest from investors reflects confidence in Novonesis, our business model and the strategic direction we have set for the company. We remain well-positioned to capture growth opportunities in the years ahead." Transaction details Novonesis, through Novozymes A/S, has successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the company's newly established EUR 4 billion Euro Medium Term Note (EMTN) Program. The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%. The Notes have been rated in line with the company's corporate credit rating of A with a stable outlook.
Novonesis has completed a €1.7 billion bond issuance to refinance the bridge facility used for its acquisition of dsm firmenich's stake in the Feed Enzyme Alliance, which closed in June 2025. The acquisition gives Novonesis full control of the alliance's sales and distribution. The bonds were issued through Novozymes A/S under a newly established €4 billion Euro Medium Term Note programme. The issuance comprises three tranches with maturities of four to eleven years and fixed interest rates between 3.25% and 4.00%. The notes will be issued on 19 March 2026 and listed on the Luxembourg Stock Exchange. They have been rated A with a stable outlook, matching Novonesis' corporate credit rating. CFO Rainer Lehmann said the strong investor interest reflects confidence in the company's business model and strategic direction.
Søren linding: Novozymes merger destroys value. Value creation has plummeted over the past five years for Novozymes, which after merging with Chr. Hansen is now called Novonesis. Operations must improve significantly to restore capital discipline to previous heights. It won't happen before 2030. March 16, 2026 at 08:03 This is a comment - it expresses the writer's opinion. It's hard to see. On the surface, everything seems to be going according to plan. Granted, growth could be higher, but in a turbulent world, it appears that Novonesis is gaining market share. Not bad. Profitability lags behind previous highs from before the acquisition of the other Danish ingredients giant Chr. Hansen in 2024. It takes time to harvest synergies... Written for companies. By those who know them Finance Quarterly Subscription for one user Unlimited access for 3 months Annual price: 5,180,- Finance Annual Subscription for one user Save 680,- Unlimited access for 12 months Annual price: 4,500,- Finance Business Subscription for multiple users Finance Business is for companies seeking a tailored solution with multiple accesses bundled in one subscription. Payment options Try Finance for 30 days - and get access to all content. Order access